The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Coronary Thrombosis

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Coronary Thrombosis


High impact information on Coronary Thrombosis


Chemical compound and disease context of Coronary Thrombosis


Biological context of Coronary Thrombosis


Anatomical context of Coronary Thrombosis

  • Thus, reduced activity and enhanced inhibition of plasma tPA may be important factors in the origin of coronary thrombosis, especially in the absence of coronary artery disease [20].
  • Lysis of the coronary thrombosis with intravenous or intracoronary administration of streptokinase or intravenous administration of one of the newer, currently experimental agents, such as tissue plasminogen activation or prourokinase, can directly restore oxygen and substrate delivery to potentially salvageable myocardium [21].

Gene context of Coronary Thrombosis


Analytical, diagnostic and therapeutic context of Coronary Thrombosis


  1. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. Burke, A.P., Farb, A., Malcom, G.T., Liang, Y.H., Smialek, J., Virmani, R. N. Engl. J. Med. (1997) [Pubmed]
  2. Active site-blocked factor IXa prevents intravascular thrombus formation in the coronary vasculature without inhibiting extravascular coagulation in a canine thrombosis model. Benedict, C.R., Ryan, J., Wolitzky, B., Ramos, R., Gerlach, M., Tijburg, P., Stern, D. J. Clin. Invest. (1991) [Pubmed]
  3. The pathogenesis of coronary plaques, thromboses, and hemorrhages: an evaluative review. Friedman, M. Circulation (1975) [Pubmed]
  4. Attenuation of the synthesis of plasminogen activator inhibitor type 1 by niacin. A potential link between lipid lowering and fibrinolysis. Brown, S.L., Sobel, B.E., Fujii, S. Circulation (1995) [Pubmed]
  5. Suppression of plasminogen activator inhibitor-1 release from human cerebral endothelium by plasminogen activators. A factor potentially predisposing to intracranial bleeding. Shatos, M.A., Doherty, J.M., Penar, P.L., Sobel, B.E. Circulation (1996) [Pubmed]
  6. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. Weiss, E.J., Bray, P.F., Tayback, M., Schulman, S.P., Kickler, T.S., Becker, L.C., Weiss, J.L., Gerstenblith, G., Goldschmidt-Clermont, P.J. N. Engl. J. Med. (1996) [Pubmed]
  7. Endogenous prostaglandin endoperoxides and prostacyclin modulate the thrombolytic activity of tissue plasminogen activator. Effects of simultaneous inhibition of thromboxane A2 synthase and blockade of thromboxane A2/prostaglandin H2 receptors in a canine model of coronary thrombosis. Golino, P., Rosolowsky, M., Yao, S.K., McNatt, J., De Clerck, F., Buja, L.M., Willerson, J.T. J. Clin. Invest. (1990) [Pubmed]
  8. Prostaglandin endoperoxides modulate the response to thromboxane synthase inhibition during coronary thrombosis. Fitzgerald, D.J., Fragetta, J., FitzGerald, G.A. J. Clin. Invest. (1988) [Pubmed]
  9. Coronary thrombolysis with recombinant tissue-type plasminogen activator. A hematologic and pharmacologic study. Topol, E.J., Bell, W.R., Weisfeldt, M.L. Ann. Intern. Med. (1985) [Pubmed]
  10. How vitronectin binds PAI-1 to modulate fibrinolysis and cell migration. Zhou, A., Huntington, J.A., Pannu, N.S., Carrell, R.W., Read, R.J. Nat. Struct. Biol. (2003) [Pubmed]
  11. Interaction between plasma potassium and epinephrine in coronary thrombosis in dogs. Lin, H., Young, D.B. Circulation (1994) [Pubmed]
  12. Acceleration of recombinant tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by the combination of heparin and the Arg-Gly-Asp-containing peptide bitistatin in a canine model of coronary thrombosis. Shebuski, R.J., Stabilito, I.J., Sitko, G.R., Polokoff, M.H. Circulation (1990) [Pubmed]
  13. Mediation of reocclusion by thromboxane A2 and serotonin after thrombolysis with tissue-type plasminogen activator in a canine preparation of coronary thrombosis. Golino, P., Ashton, J.H., Glas-Greenwalt, P., McNatt, J., Buja, L.M., Willerson, J.T. Circulation (1988) [Pubmed]
  14. Opposing effects of plasma epinephrine and norepinephrine on coronary thrombosis in vivo. Lin, H., Young, D.B. Circulation (1995) [Pubmed]
  15. Human platelet Ca2+ mobilization, glycoprotein IIb/IIIa activation, and experimental coronary thrombosis in vivo in dogs are all inhibited by the inotropic agent amrinone. Sill, J.C., Bertha, B., Berger, I., Uhl, C., Nugent, M., Folts, J. Circulation (1997) [Pubmed]
  16. Modifiable risk factors for vascular access site complications in the IMPACT II Trial of angioplasty with versus without eptifibatide. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. Mandak, J.S., Blankenship, J.C., Gardner, L.H., Berkowitz, S.D., Aguirre, F.V., Sigmon, K.N., Timmis, G.C., Gilchrist, I.C., McIvor, M., Resar, J., Weiner, B.H., George, B.S., Talley, J.D., Lincoff, A.M., Tcheng, J.E., Califf, R.M., Topol, E.J. J. Am. Coll. Cardiol. (1998) [Pubmed]
  17. Endothelin-1 production in coronary circulation in a new canine model of coronary thrombosis. Fujikawa, H., Kawasaki, K., Sekiguchi, H., Mito, H., Hayashi, Y., Funayama, H., Shimada, K. Cardiovasc. Res. (1996) [Pubmed]
  18. Coronary artery wall atherosclerosis in relation to the estrogen receptor 1 gene polymorphism: an autopsy study. Lehtimäki, T., Kunnas, T.A., Mattila, K.M., Perola, M., Penttilä, A., Koivula, T., Karhunen, P.J. J. Mol. Med. (2002) [Pubmed]
  19. Coronary thrombosis in a patient with May-Hegglin anomaly. McDunn, S., Hartz, W., Ts'Ao, C., Green, D. Am. J. Clin. Pathol. (1991) [Pubmed]
  20. Tissue plasminogen activator activity and inhibition in acute myocardial infarction and angiographically normal coronary arteries. Verheugt, F.W., ten Cate, J.W., Sturk, A., Imandt, L., Verhorst, P.M., van Eenige, M.J., Verwey, W., Roos, J.P. Am. J. Cardiol. (1987) [Pubmed]
  21. Role of nitrates in acute myocardial infarction. Flaherty, J.T. Am. J. Cardiol. (1987) [Pubmed]
  22. Tumor necrosis factor alpha activates the human plasminogen activator inhibitor-1 gene through a distal nuclear factor kappaB site. Hou, B., Eren, M., Painter, C.A., Covington, J.W., Dixon, J.D., Schoenhard, J.A., Vaughan, D.E. J. Biol. Chem. (2004) [Pubmed]
  23. Comparison of desulfatohirudin (REVASC) and heparin as adjuncts to thrombolytic therapy with reteplase in a canine model of coronary thrombosis. Martin, U., Dörge, L., Fischer, S. Br. J. Pharmacol. (1996) [Pubmed]
  24. Matrix metalloproteinase3 and 9 gene promoter polymorphisms: joint action of two loci as a risk factor for coronary artery complicated plaques. Pöllänen, P.J., Lehtimäki, T., Mikkelsson, J., Ilveskoski, E., Kunnas, T., Perola, M., Penttilä, A., Mattila, K.M., Nikkari, S.T., Syrjäkoski, K., Karhunen, P.J. Atherosclerosis (2005) [Pubmed]
  25. Platelet membrane collagen receptor glycoprotein VI polymorphism is associated with coronary thrombosis and fatal myocardial infarction in middle-aged men. Ollikainen, E., Mikkelsson, J., Perola, M., Penttilä, A., Karhunen, P.J. Atherosclerosis (2004) [Pubmed]
  26. Simultaneous administration of thromboxane A2- and serotonin S2-receptor antagonists markedly enhances thrombolysis and prevents or delays reocclusion after tissue-type plasminogen activator in a canine model of coronary thrombosis. Golino, P., Ashton, J.H., McNatt, J., Glas-Greenwalt, P., Yao, S.K., O'Brien, R.A., Buja, L.M., Willerson, J.T. Circulation (1989) [Pubmed]
  27. Influence of heparin and systemic lysis on coronary blood flow after reperfusion induced by the novel recombinant plasminogen activator BM 06.022 in a canine model of coronary thrombosis. Martin, U., Fischer, S., Sponer, G. J. Am. Coll. Cardiol. (1993) [Pubmed]
  28. Influence of prostacyclin on coronary thrombosis and myocardial ischemia in conscious canine experiments. Fiedler, V.B., Mardin, M. Archives internationales de pharmacodynamie et de thérapie. (1985) [Pubmed]
WikiGenes - Universities